148 related articles for article (PubMed ID: 27485537)
21. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
[TBL] [Abstract][Full Text] [Related]
22. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
23. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.
Mizuno T; Terada T; Kamba T; Fukudo M; Katsura T; Nakamura E; Ogawa O; Inui K
Ann Oncol; 2010 Jun; 21(6):1382-1383. PubMed ID: 20348146
[No Abstract] [Full Text] [Related]
24. Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients.
Watanabe A; Yamamoto K; Ioroi T; Hirata S; Harada K; Miyake H; Fujisawa M; Nakagawa T; Yano I; Hirai M
Biol Pharm Bull; 2017; 40(4):458-464. PubMed ID: 28381801
[TBL] [Abstract][Full Text] [Related]
25. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
Narjoz C; Cessot A; Thomas-Schoemann A; Golmard JL; Huillard O; Boudou-Rouquette P; Behouche A; Taieb F; Durand JP; Dauphin A; Coriat R; Vidal M; Tod M; Alexandre J; Loriot MA; Goldwasser F; Blanchet B
Invest New Drugs; 2015 Feb; 33(1):257-68. PubMed ID: 25344452
[TBL] [Abstract][Full Text] [Related]
26. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.
Teo YL; Chong XJ; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
Cancer Chemother Pharmacol; 2014 Feb; 73(2):381-8. PubMed ID: 24306119
[TBL] [Abstract][Full Text] [Related]
27. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Kruse V; Somers A; Van Bortel L; De Both A; Van Belle S; Rottey S
J Clin Pharm Ther; 2014 Jun; 39(3):259-65. PubMed ID: 24417304
[TBL] [Abstract][Full Text] [Related]
28. Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.
de Wit D; van Erp NP; Khosravan R; Wiltshire R; Allred R; Demetri GD; Guchelaar HJ; Gelderblom H
BMC Cancer; 2014 Aug; 14():575. PubMed ID: 25102852
[TBL] [Abstract][Full Text] [Related]
29. Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
Kloth JS; Binkhorst L; de Wit AS; de Bruijn P; Hamberg P; Lam MH; Burger H; Chaves I; Wiemer EA; van der Horst GT; Mathijssen RH
Clin Pharmacokinet; 2015 Aug; 54(8):851-8. PubMed ID: 25647628
[TBL] [Abstract][Full Text] [Related]
30. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
31. Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report.
Takasaki S; Kikuchi M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
J Med Case Rep; 2017 Feb; 11(1):28. PubMed ID: 28143610
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.
Zhang CJ; Zhao PJ; Li XS; Zhao J; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; He ZS; Jin J; Zhou LQ
Chin Med J (Engl); 2013; 126(15):2826-9. PubMed ID: 23924450
[TBL] [Abstract][Full Text] [Related]
33. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule.
Ohba K; Miyata Y; Yasuda T; Asai A; Mitsunari K; Matsuo T; Mochizuki Y; Matsunaga N; Sakai H
Asia Pac J Clin Oncol; 2018 Jun; 14(3):153-158. PubMed ID: 29383843
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study.
Kloth JS; Klümpen HJ; Yu H; Eechoute K; Samer CF; Kam BL; Huitema AD; Daali Y; Zwinderman AH; Balakrishnar B; Bennink RJ; Wong M; Schellens JH; Mathijssen RH; Gurney H
Clin Pharmacokinet; 2014 Mar; 53(3):261-269. PubMed ID: 24234588
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer.
Gandhi KA; Joshi A; Mehta P; Gurjar M; Rane P; Sharma J; Patil A; Nookala M; Noronha V; Prabhash K; Gota V
Cancer Chemother Pharmacol; 2022 Jun; 89(6):751-759. PubMed ID: 35441269
[TBL] [Abstract][Full Text] [Related]
37. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
38. Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.
Ravaud A; Bello CL
Anticancer Drugs; 2011 Jun; 22(5):377-83. PubMed ID: 21394020
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of sunitinib in hemodialysis.
Izzedine H; Etienne-Grimaldi MC; Renée N; Vignot S; Milano G
Ann Oncol; 2009 Jan; 20(1):190-2. PubMed ID: 18801884
[No Abstract] [Full Text] [Related]
40. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
